They have at least one thing in common: An exciting pipeline.

Driven by looming patent cliffs, newly buoyant public markets, and Big Pharma's race to beef up their pipelines, dealmaking in 2026 is off to a strong start.

Biopharma dealmaking is driven by pressure to top up drug pipelines ahead of major patent expirations later this decade.

It's important to consider your comfort with risk before diving in.

Veraxa Biotech (VRXA) rated Sell: shares look overvalued post‑SPAC. The pipeline’s fragility is pronounced. See here for more ...

VERAXA Biotech AG (NASDAQ: VRXA; “VERAXA”), an emerging leader in designing novel cancer therapies, today announced that the Company has generated new in vitro proof-of-concept data validating its ...

US lawmakers push Treasury to screen outbound biotech investments in China under the COINS Act. BINSA bill targets ...

As AI transforms biology, longevity startups are attracting investors, advancing toward clinical milestones, and reshaping ...

MapLight Therapeutics, part of the 2025 biotech IPO class, has "separated" from the CFO who took it public. Here's what we ...

EU health ministers split over a proposal to give certain innovative medicines an extra year of market protection, with EU ...

As the technology transforms scientific discovery, industry players are also grappling with the extent of its real-world use ...

Biotech stocks are considered extremely high-risk, high-reward investments. Many biotech companies are developing one or more ...